A
Andrew D. Goodman
Researcher at University of Rochester
Publications - 125
Citations - 10468
Andrew D. Goodman is an academic researcher from University of Rochester. The author has contributed to research in topics: Multiple sclerosis & Expanded Disability Status Scale. The author has an hindex of 49, co-authored 122 publications receiving 9296 citations. Previous affiliations of Andrew D. Goodman include National Institutes of Health & University of Rochester Medical Center.
Papers
More filters
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Andrew D. Goodman,Theodore R Brown,Lauren B. Krupp,Randall T Schapiro,Steven R. Schwid,Ron Cohen,Lawrence Marinucci,Andrew R. Blight +7 more
TL;DR: Fampridine improved walking ability in some people with multiple sclerosis, and was associated with a reduction of patients' reported ambulatory disability, and is a clinically meaningful therapeutic benefit.
Journal ArticleDOI
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky,Ponnada A. Narayana,Paul O'Connor,P. K. Coyle,Corey C. Ford,Kenneth P. Johnson,Kenneth P. Johnson,Aaron Miller,Aaron Miller,Lillian Pardo,Shaul Kadosh,David Ladkani,Lorne F. Kastrukoff,Pierre Duquette,Mark S. Freedman,Marc Debouverie,Catherine Lubetski,Gilles Edan,E Roullet,Christian Confavreux,Alan J. Thompson,L D Blumhardt,L D Blumhardt,Stanley Hawkins,Thomas F. Scott,Daniel Wynn,Joanna Cooper,Stephen Thurston,Stanton B. Elias,Clyde E. Markowitz,David Mattson,John H. Noseworthy,Elizabeth A. Shuster,Jonathan L. Carter,Fred D. Lublin,WH Stuart,Michael D. Kaufman,Gary Birnbaum,Kottil Rammohan,Ruth H. Whitham,Cornelia Mihai,Steven J. Greenberg,Craig M. Smith,Mark A. Agius,Stan Van Den Noort,Lawrence W. Myers,James G. Nelson,Douglas S. Goodin,Barry G. W. Arnason,Khurram Bashir,Sharon G. Lynch,Patricia K. Coyle,Stephen Kamin,William A. Sheremata,Galen Mitchell,Andrew D. Goodman,Norman J Kachuck,Peter B. Dunne,J. William Lindsey,Elliot M. Frohman,James D. Bowen,Benjamin Rix Brooks,John W. Rose,Harold L. Moses,Douglas Jeffrey,Anne H. Cross,Robert P. Lisak,Timothy Vollmer,Jack P. Antel,Gary Cutter,Luanne M. Metz,Henry F. McFarland,Steven Reingold,Fred D. Lublin,Irina Vainrub,Lucie Lambert,Fengwei Zhong,Jeff Rasmituth,Saria Momin,Rivka Kreitman,Galia Shifroni,Irit Pinchasi,Yafit Stark +82 more
TL;DR: To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.
Journal ArticleDOI
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Jeffrey A. Cohen,Gary Cutter,J. S. Fischer,Andrew D. Goodman,Fedor Heidenreich,Mariska F. Kooijmans,Alfred Sandrock,Richard A. Rudick,Jack H. Simon,N. A. Simonian,E. C. Tsao,John N. Whitaker +11 more
TL;DR: IFN&bgr;-1a demonstrated benefit on MSFC progression, relapses, quality of life, and MRI activity in SPMS.
Journal ArticleDOI
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Andrew D. Goodman,Andrew D. Goodman,Theodore R Brown,Keith R. Edwards,Lauren B. Krupp,Randall T Schapiro,Ron Cohen,Lawrence Marinucci,Andrew R. Blight +8 more
TL;DR: This phase 3 study was designed to confirm efficacy and further define safety and pharmacodynamics in multiple sclerosis patients treated with oral, extended‐release dalfampridine (4‐aminopyridine) 10mg twice daily.